Lamar Brown

Bioactivity of AAV2‐neurturin gene therapy (CERE‐120): Differences between Parkinson's disease and nonhuman primate brains

Raymond T. Bartus, Christopher D. Herzog, Yaping Chu et al. · Movement Disorders · 2010 · 169 citations

Life Sciences, Neurology, Neuroscience +17

Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies

Raymond T. Bartus, Jeffrey H. Kordower, Eugene M. Johnson et al. · Neurobiology of Disease · 2015 · 81 citations · Full text

Life Sciences, Neurology, Neuroscience +12

EXPRESSION, BIOACTIVITY, AND SAFETY 1 YEAR AFTER ADENO-ASSOCIATED VIRAL VECTOR TYPE 2–MEDIATED DELIVERY OF NEURTURIN TO THE MONKEY NIGROSTRIATAL SYSTEM SUPPORT CERE-120 FOR PARKINSON'S DISEASE

Christopher D. Herzog, Lamar Brown, Dawn Gammon et al. · Neurosurgery · 2009 · 75 citations

Life Sciences, Neurobiology, Neuroscience +17

Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: Support for nigral targeting in Parkinson's disease

Raymond T. Bartus, Lamar Brown, Alistair Wilson et al. · Neurobiology of Disease · 2011 · 62 citations · Full text

Medicine, Neurology, Neuroscience +16

Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120)

Christopher D. Herzog, Lamar Brown, Brian Kruegel et al. · Neurobiology of Disease · 2013 · 44 citations · Full text

Life Sciences, Neurobiology, Neuroscience +16